GLEOSTINE Drug Patent Profile
Which patents cover Gleostine, and what generic alternatives are available?
Gleostine is a drug marketed by Azurity and is included in one NDA.
The generic ingredient in GLEOSTINE is lomustine. There is one drug master file entry for this compound. Four suppliers are listed for this compound. Additional details are available on the lomustine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Gleostine
A generic version of GLEOSTINE was approved as lomustine by CARNEGIE on October 27th, 2025.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for GLEOSTINE?
- What are the global sales for GLEOSTINE?
- What is Average Wholesale Price for GLEOSTINE?
Summary for GLEOSTINE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 88 |
| Clinical Trials: | 13 |
| Patent Applications: | 4,731 |
| Drug Prices: | Drug price information for GLEOSTINE |
| What excipients (inactive ingredients) are in GLEOSTINE? | GLEOSTINE excipients list |
| DailyMed Link: | GLEOSTINE at DailyMed |
Recent Clinical Trials for GLEOSTINE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Cancer Institute (NCI) | Phase 3 |
| NRG Oncology | Phase 3 |
| Emory University | Early Phase 1 |
Pharmacology for GLEOSTINE
| Drug Class | Alkylating Drug |
| Mechanism of Action | Alkylating Activity |
US Patents and Regulatory Information for GLEOSTINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Azurity | GLEOSTINE | lomustine | CAPSULE;ORAL | 017588-004 | Dec 19, 2014 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Azurity | GLEOSTINE | lomustine | CAPSULE;ORAL | 017588-003 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Azurity | GLEOSTINE | lomustine | CAPSULE;ORAL | 017588-001 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Azurity | GLEOSTINE | lomustine | CAPSULE;ORAL | 017588-002 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Gleostine Market Dynamics, Patent Exclusivity, Pricing and Financial Trajectory
Gleostine is the U.S. brand for lomustine, an oral alkylating chemotherapy used primarily for recurrent or progressive brain tumors, including glioblastoma. The product has no meaningful remaining originator patent exclusivity, but NextSource Pharma has maintained commercial control through brand positioning, limited generic competition, manufacturing complexity and oncology distribution channels. Its financial trajectory has been driven more by price increases and supply control than by substantial volume growth.
The principal commercial risks are generic entry, payer restrictions, Medicare price negotiation, oncology treatment changes and the limited size of the eligible patient population. The principal defenses are the product’s established clinical use, oral delivery, relatively concentrated distribution and the absence of a widely available substitutable generic product in the U.S.
What is Gleostine and how is it used?
Gleostine contains lomustine, an oral nitrosourea alkylating agent. The FDA-approved product is supplied as capsules in 10 mg, 40 mg and 100 mg strengths. The product is administered orally and is generally dosed at extended intervals because of delayed and cumulative myelosuppression.[1]
| Attribute | Gleostine detail |
|---|---|
| Active ingredient | Lomustine |
| U.S. brand | Gleostine |
| Dosage form | Oral capsules |
| U.S. NDA | NDA 016680 |
| Original FDA approval | 1976 |
| Current commercial company | NextSource Pharma |
| Main treatment area | Recurrent or progressive brain tumors |
| Key clinical use | Recurrent glioblastoma and other malignant brain tumors |
| Regulatory category | Conventional small-molecule drug |
| Biosimilar pathway | Not applicable |
Lomustine is also used in combination regimens and in clinical practice for other cancers, including lymphoma. Gleostine’s commercial value is concentrated in neuro-oncology, where treatment options after recurrence are limited and physicians may continue to use lomustine despite modest clinical benefit.
The product is not a biologic. Biosimilar competition is therefore irrelevant. Any direct competitive entry would occur through an abbreviated new drug application, a competing lomustine product, compounding, or therapeutic substitution with another brain-tumor treatment.
What is the FDA regulatory status of Gleostine?
Gleostine is an FDA-approved prescription drug with a legacy NDA. The FDA label identifies lomustine as an antineoplastic agent for use in brain tumors and Hodgkin lymphoma.[1]
The product does not depend on a modern 505(b)(2) approval for its core regulatory status. Its original approval predates current Hatch-Waxman practices. Because the active ingredient and dosage form have been established for decades, the central regulatory question for a competing manufacturer is whether it can demonstrate pharmaceutical equivalence, bioequivalence and adequate manufacturing controls.
The product has several regulatory characteristics that affect market competition:
- Lomustine is a cytotoxic chemotherapy with narrow therapeutic margins.
- Dose strengths are differentiated by capsule size and color.
- Manufacturing requires controls appropriate for a hazardous active pharmaceutical ingredient.
- Delayed hematologic toxicity makes labeling, dose administration and clinical monitoring important.
- The product is distributed through specialty and oncology channels rather than broad retail pharmacy channels.
These factors can raise the operational cost of generic entry, but they do not create regulatory exclusivity.
What patents protect Gleostine?
Gleostine’s commercial protection is not based on a current, high-value patent estate covering the lomustine molecule. Lomustine was disclosed and approved decades ago, and any original compound patent protection has expired.
Public FDA Orange Book records should be reviewed for the current listing status of NDA 016680. The commercially relevant conclusion is that Gleostine’s market position is primarily non-patent based. The principal protection mechanisms are brand recognition, supply reliability, clinical familiarity, distribution control and the limited economic attractiveness of producing a low-volume cytotoxic capsule.
| Protection category | Gleostine position |
|---|---|
| Original compound patent | Expired |
| Original formulation patent | Expired or commercially immaterial |
| Current blocking patent estate | No material public estate identified |
| Method-of-use patents | No material public exclusivity identified |
| FDA orphan exclusivity | No current exclusivity identified |
| Pediatric exclusivity | No current exclusivity identified |
| Biosimilar exclusivity | Not applicable |
| Orange Book strategy | No known active patent barrier central to the product’s value |
What formulations are protected by Gleostine patents?
The marketed formulation is a conventional oral capsule containing lomustine. The capsule, strength and excipient system do not appear to provide a durable, commercially important patent barrier.
A manufacturer seeking to compete could attempt to develop a bioequivalent capsule rather than reproduce a proprietary extended-release, liposomal or implantable delivery system. This materially lowers the technical barrier compared with products protected by complex delivery platforms.
The absence of a meaningful formulation patent is important. A generic competitor would not need to develop a new brain-penetrating system or demonstrate clinical superiority. It would generally seek to match the reference product’s active ingredient, dosage form, strength and bioavailability.
When does Gleostine lose exclusivity?
Gleostine’s statutory exclusivity has effectively expired. The product was approved in 1976, long before the modern five-year new chemical entity exclusivity framework. Its original patent term also expired decades ago.
| Exclusivity category | Status |
|---|---|
| FDA approval | Active |
| New chemical entity exclusivity | Expired |
| Original patent exclusivity | Expired |
| Orphan-drug exclusivity | No current exclusivity identified |
| Pediatric exclusivity | None currently relevant |
| Patent term extension | No commercially relevant current extension identified |
| Regulatory monopoly | None identified |
The distinction between exclusivity and market availability is central. Gleostine can remain the only widely marketed U.S. lomustine product even after legal exclusivity has expired. That outcome reflects supply economics and commercial strategy, not a continuing patent monopoly.
Does Gleostine have an Orange Book listing?
Gleostine’s Orange Book position should be treated separately from its FDA approval. An Orange Book listing only creates a patent-related notice mechanism for an approved product. It does not establish that the product has active market exclusivity.
For Gleostine, the relevant public record does not indicate a current patent portfolio that materially blocks a generic lomustine capsule. Any patent listed for the NDA would need to be evaluated by claim scope, expiration date and whether the claim covers the active commercial product.
The practical conclusion is that a generic applicant could likely rely on the absence of an effective patent barrier or certify against any listed patent that does not block the proposed product.
Which companies are challenging Gleostine, and are there Paragraph IV risks?
No widely documented, commercially significant Paragraph IV litigation campaign against Gleostine has established a new generic market in the way seen for major small-molecule blockbusters. Publicly visible litigation activity has instead centered on pricing, access and commercial conduct rather than a material patent challenge to an active Gleostine estate.
A generic applicant could pursue one of several pathways:
- File an ANDA with a Paragraph III certification if a listed patent remains in force but does not require immediate launch.
- File an ANDA with a Paragraph IV certification if it believes a listed patent is invalid, unenforceable or not infringed.
- Rely on a no-patent certification where the Orange Book contains no blocking patent.
- Develop a product after evaluating manufacturing, supply and market-access economics.
The absence of a major Paragraph IV record does not eliminate generic risk. It indicates that the commercial impediments may be greater than the legal impediments. A potential entrant would need to estimate whether the U.S. market can support validation, hazardous-drug manufacturing, pharmacovigilance, inventory and payer contracting costs.
What patent litigation affects Gleostine?
The principal public controversy surrounding Gleostine has involved pricing rather than patent enforcement. In 2019, the U.S. Senate Finance Committee examined the product’s price increases and the effect on Medicare spending and patient access.[2]
The committee reported that the price of Gleostine increased sharply after NextSource obtained commercial rights. Reported increases varied by capsule strength and time period, but the investigation described a rise of more than 1,400% over several years. The report linked the price increases to higher Medicare spending and increased patient cost exposure.[2]
This history creates litigation and regulatory risk even without an active patent dispute:
- Government scrutiny of pricing practices.
- Payer pressure for prior authorization and step therapy.
- Patient-assistance program costs.
- Reputational damage among oncology providers.
- Potential exposure to Medicare price-control measures.
- Greater commercial attractiveness for alternative suppliers.
No public patent settlement has established a delayed generic-entry date comparable with settlements involving highly patented branded drugs.
How has Gleostine pricing changed?
Gleostine’s price trajectory has been the central commercial feature of the product.
Before NextSource’s commercial control, lomustine was an inexpensive, long-established chemotherapy. Following the change in ownership and marketing, the product price increased substantially. The Senate Finance Committee reported that the price of a 100 mg capsule rose from approximately $50 to more than $700 over the period examined, representing an increase of more than 1,400%.[2]
Reported pricing has varied by year, strength, channel and negotiated discount. List price is not the same as net price, and Medicare reimbursement data include dispensing, plan and beneficiary components. Even after discounts, the product generated materially higher revenue per treated patient than its historical price would have produced.
| Commercial driver | Effect on Gleostine |
|---|---|
| Higher price per capsule | Increased revenue without proportional volume growth |
| Small eligible population | Limits unit expansion |
| Recurrent brain-tumor use | Supports continued specialist demand |
| Oral administration | Avoids infusion-center administration |
| Limited generic availability | Preserves price control |
| Medicare exposure | Increases policy and reimbursement risk |
| Specialty distribution | Supports channel control but limits scale |
What is Gleostine’s financial trajectory?
NextSource is privately held, so consolidated Gleostine revenue, gross margin and cash flow are not disclosed with the consistency of a public pharmaceutical company. Public Medicare data and government investigations provide the clearest view of the product’s financial trajectory.
The financial pattern has four stages:
Pre-acquisition period
Lomustine was a mature, low-priced oncology product with limited commercial investment. Revenue was constrained by an aging product profile and a relatively narrow treatment population.
Commercial repricing period
After NextSource assumed control, price increases materially expanded revenue per patient. This period produced the sharpest change in the product’s financial profile.
Scrutiny period
Government investigations, oncology criticism and payer pressure increased after the pricing changes became public. The product continued to generate revenue, but its commercial model became more exposed to reimbursement policy and political scrutiny.
Mature specialty-product period
Gleostine now operates as a mature specialty oncology product. Growth is more likely to come from price, preservation of prescribing share, expanded use within recurrent brain tumors and continued lack of generic supply than from a large increase in patient volume.
Medicare Part D data cited by the Senate Finance Committee showed substantial spending on Gleostine despite the small number of treated patients.[2] That spending profile indicates high revenue concentration per patient and significant sensitivity to a single reimbursement decision.
How much revenue exposure does Gleostine have to Medicare?
Gleostine has unusually high Medicare exposure for a product with a small treated population. Recurrent glioblastoma occurs primarily in older adults, and many patients are eligible for Medicare. The product is administered orally, so reimbursement flows through prescription-drug coverage rather than primarily through hospital outpatient administration.
The revenue implications are direct:
- Medicare policy changes can affect a large portion of demand.
- Beneficiary cost sharing can reduce adherence or treatment initiation.
- Part D plan restrictions can redirect prescribing.
- Negotiated prices can reduce manufacturer net revenue.
- Government reporting makes price increases more visible.
The Inflation Reduction Act introduced Medicare drug-price negotiation for selected high-expenditure products. Whether and when lomustine is selected depends on statutory eligibility, product classification, inclusion of generic or biosimilar competition and CMS selection decisions. The product’s age and lack of current patent exclusivity may reduce the likelihood of a long-term protected-price position, but public policy remains a material risk to future net pricing.[3]
What generic launch risks exist for Gleostine?
Generic launch is legally feasible but commercially uncertain. The strongest generic-entry scenario would involve a manufacturer with existing oncology or hazardous-drug production infrastructure and an established specialty distribution network.
Generic launch barriers
A competitor would face:
- Low absolute patient volume.
- Hazardous-drug manufacturing requirements.
- Product-specific bioequivalence and stability work.
- Inventory and shortage-management obligations.
- Limited opportunity to build physician demand.
- Payer contracting costs.
- Potential price compression after entry.
- Difficulty competing against an incumbent with established supply channels.
Generic launch scenarios
| Scenario | Market effect | Estimated commercial implication |
|---|---|---|
| No generic entrant | Brand retains high gross-to-net pricing | Highest revenue durability |
| One generic entrant | Selective payer substitution | Moderate price erosion |
| Two or more generics | Broad formulary substitution | Significant net-price decline |
| Supply-constrained generic | Limited practical substitution | Brand retains share |
| Multiple reliable generics | Commodity-style competition | Sharp revenue and margin decline |
A single generic does not necessarily destroy the market. Oncology products can experience uneven substitution when hospitals and specialty pharmacies prioritize supply continuity. Two or more reliable suppliers would create a more serious threat.
How strong is the Gleostine patent estate?
The patent estate is weak as a legal exclusivity asset and stronger as a commercial-control asset.
| Dimension | Assessment |
|---|---|
| Molecule protection | Weak; expired |
| Formulation protection | Weak |
| Method-of-use protection | No material current barrier identified |
| Regulatory exclusivity | Expired |
| Manufacturing know-how | Moderate operational value |
| Supply-chain control | Moderate to strong |
| Brand recognition | Moderate in neuro-oncology |
| Generic deterrence | Commercial rather than legal |
| Litigation leverage | Limited |
| Long-term defensibility | Dependent on supply and market structure |
The distinction matters for valuation. A buyer should not underwrite Gleostine as a patent-protected asset. The appropriate valuation framework is a mature specialty product with price and supply advantages, declining legal protection and binary generic-entry exposure.
How does Gleostine compare with competing brain-tumor drugs?
Gleostine competes with temozolomide, bevacizumab, tumor-treating fields, clinical trials and supportive-care regimens. The competitive set differs by treatment line and patient condition.
| Product or therapy | Main role | Competitive relationship |
|---|---|---|
| Gleostine | Recurrent or progressive brain tumors | Oral chemotherapy option |
| Temozolomide | Newly diagnosed and recurrent glioblastoma | More established first-line role |
| Bevacizumab | Recurrent glioblastoma and symptom control | Alternative systemic therapy |
| Tumor-treating fields | Device-based glioblastoma therapy | Different delivery and treatment model |
| Clinical trials | Investigational recurrent disease options | Can displace standard therapy |
| Supportive care | Symptom and quality-of-life management | May replace active therapy in frail patients |
Temozolomide has a broader and more established glioblastoma role. Gleostine’s value is concentrated in recurrent disease, where treatment decisions are individualized and clinical options are limited. This supports persistence but constrains market expansion.
What licensing deals and ownership changes affect Gleostine?
Gleostine’s commercial history is linked to ownership and licensing transactions rather than the creation of a new molecular franchise. NextSource obtained rights to commercialize the product in the United States and used those rights to reposition it as a specialty oncology product.
The ownership structure is commercially important because the company controlling the brand can set list price, manage distribution and determine the level of generic-response investment. Unlike a multinational pharmaceutical product with multiple regional licensees, Gleostine’s value is concentrated in U.S. commercialization.
No widely reported licensing arrangement has created a broad international patent moat around lomustine. Geographic value is therefore uneven:
- United States: highest commercial significance.
- Europe: fragmented market and country-specific reimbursement.
- Other markets: generally lower pricing and greater generic availability.
- Manufacturing jurisdictions: dependent on API and capsule supply arrangements.
What manufacturing and intellectual-property barriers affect Gleostine?
The principal manufacturing barrier is not a proprietary process patent. It is the practical cost of producing and distributing a cytotoxic oral oncology product at relatively low volume.
Potential barriers include:
- Handling and containment of lomustine.
- Qualified API sourcing.
- Capsule filling and cross-contamination controls.
- Stability testing across multiple strengths.
- Packaging and labeling requirements.
- Pharmacovigilance for delayed myelosuppression.
- Reliable distribution to oncology practices and specialty pharmacies.
These conditions can support a narrow branded market after patent expiry. They do not prevent a capable generic manufacturer from entering if expected price and volume justify investment.
Key Takeaways
- Gleostine is the U.S. brand for lomustine, an oral nitrosourea approved in 1976.
- Its original compound and regulatory exclusivity have expired.
- No material current patent estate has been identified as the primary commercial defense.
- The product’s market position depends on supply control, specialist prescribing and limited generic availability.
- Price increases, rather than major volume growth, drove the product’s financial expansion.
- Medicare is a major revenue and policy exposure because recurrent glioblastoma patients are often older adults.
- Generic entry is legally feasible but commercially constrained by low volume, hazardous-drug manufacturing and specialty distribution.
- One reliable generic could pressure price selectively; multiple suppliers would create substantial revenue erosion.
- Biosimilar competition is not relevant because lomustine is a conventional small-molecule drug.
- Gleostine should be valued as a mature specialty product with significant generic-entry and reimbursement risk, not as a patent-protected franchise.
FAQs
Is Gleostine still patent protected?
No material current patent protection appears to block competition with a conventional lomustine capsule. The original molecular and regulatory protections expired long ago.
Is there a generic version of Gleostine?
Generic lomustine availability in the United States has been limited and inconsistent. The absence of broad generic supply reflects commercial and manufacturing conditions rather than continuing originator exclusivity.
Is Gleostine included in Medicare Part D?
Yes. Gleostine is an oral prescription chemotherapy and is generally processed through prescription-drug coverage, including Medicare Part D, subject to plan rules and utilization management.
Why is Gleostine expensive despite being an old chemotherapy drug?
The product’s price increased after commercial rights changed hands. Its high price reflects market control, limited competition and specialty distribution rather than recent discovery or active molecule patents.
Could a generic manufacturer launch lomustine without infringing Gleostine patents?
A generic manufacturer could potentially enter after evaluating the current Orange Book record, applicable certifications and regulatory requirements. The principal obstacles are expected market economics, manufacturing controls and supply execution.
References
-
U.S. Food and Drug Administration. (2024). Gleostine (lomustine) prescribing information. FDA.
-
U.S. Senate Committee on Finance. (2019). Drug pricing investigation: Examining the price of cancer drugs. U.S. Government Publishing Office.
-
Centers for Medicare & Medicaid Services. (2024). Medicare Drug Price Negotiation Program. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. FDA.
-
National Cancer Institute. (2024). Lomustine. National Institutes of Health.
More… ↓


